Longest Follow-Up for ICI Plus TKI Favours Treatment with Avelumab Plus Axitinib Combination versus Sunitinib in Patients with Advanced RCC By Ogkologos - February 11, 2025 858 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from a final analysis of the JAVELIN Renal 101 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR EMA Recommends Granting a Conditional Marketing Authorisation for Amivantamab October 29, 2021 FDA Approves Zenocutuzumab-zbco for Advanced, Unresectable or Metastatic Cholangiocarcinoma May 20, 2026 How I Took Charge of My Cancer Care and Found a... August 30, 2022 EMA Recommends Extension of Therapeutic Indications for Daratumumab October 14, 2024 Load more HOT NEWS When You and Your Child Have VHL: 8 Ways to Cope EMA Recommends Granting a Marketing Authorisation for Melphalan How Sharing My Story Helps Me Cope With an Advanced Brain... Respuestas a sus preguntas sobre la vacuna contra el COVID-19
